JP2010535252A5 - - Google Patents

Download PDF

Info

Publication number
JP2010535252A5
JP2010535252A5 JP2010520219A JP2010520219A JP2010535252A5 JP 2010535252 A5 JP2010535252 A5 JP 2010535252A5 JP 2010520219 A JP2010520219 A JP 2010520219A JP 2010520219 A JP2010520219 A JP 2010520219A JP 2010535252 A5 JP2010535252 A5 JP 2010535252A5
Authority
JP
Japan
Prior art keywords
compound
diabetes
type
metabolic
nachr agonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010520219A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010535252A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/071893 external-priority patent/WO2009018511A2/en
Publication of JP2010535252A publication Critical patent/JP2010535252A/ja
Publication of JP2010535252A5 publication Critical patent/JP2010535252A5/ja
Pending legal-status Critical Current

Links

JP2010520219A 2007-08-02 2008-08-01 代謝障害を治療または予防するためのα7nAChRアゴニスト Pending JP2010535252A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US95361407P 2007-08-02 2007-08-02
US95361307P 2007-08-02 2007-08-02
US95361007P 2007-08-02 2007-08-02
US97165407P 2007-09-12 2007-09-12
PCT/US2008/071893 WO2009018511A2 (en) 2007-08-02 2008-08-01 Alpha7 nachr agonists for treating or preventing metabolic disorders

Publications (2)

Publication Number Publication Date
JP2010535252A JP2010535252A (ja) 2010-11-18
JP2010535252A5 true JP2010535252A5 (enExample) 2011-01-06

Family

ID=39945177

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2010520219A Pending JP2010535252A (ja) 2007-08-02 2008-08-01 代謝障害を治療または予防するためのα7nAChRアゴニスト
JP2010520213A Active JP5358573B2 (ja) 2007-08-02 2008-08-01 (2s,3r)−n−(2−((3−ピリジニル)メチル)−1−アザビシクロ[2.2.2]オクタ−3−イル)ベンゾフラン−2−カルボキサミド、その新規塩形態およびその使用方法
JP2013148087A Active JP5852611B2 (ja) 2007-08-02 2013-07-17 (2s,3r)−n−(2−((3−ピリジニル)メチル)−1−アザビシクロ[2.2.2]オクタ−3−イル)ベンゾフラン−2−カルボキサミド、その新規塩形態およびその使用方法
JP2013148091A Active JP6106549B2 (ja) 2007-08-02 2013-07-17 (2s,3r)−n−(2−((3−ピリジニル)メチル)−1−アザビシクロ[2.2.2]オクタ−3−イル)ベンゾフラン−2−カルボキサミド、その新規塩形態およびその使用方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2010520213A Active JP5358573B2 (ja) 2007-08-02 2008-08-01 (2s,3r)−n−(2−((3−ピリジニル)メチル)−1−アザビシクロ[2.2.2]オクタ−3−イル)ベンゾフラン−2−カルボキサミド、その新規塩形態およびその使用方法
JP2013148087A Active JP5852611B2 (ja) 2007-08-02 2013-07-17 (2s,3r)−n−(2−((3−ピリジニル)メチル)−1−アザビシクロ[2.2.2]オクタ−3−イル)ベンゾフラン−2−カルボキサミド、その新規塩形態およびその使用方法
JP2013148091A Active JP6106549B2 (ja) 2007-08-02 2013-07-17 (2s,3r)−n−(2−((3−ピリジニル)メチル)−1−アザビシクロ[2.2.2]オクタ−3−イル)ベンゾフラン−2−カルボキサミド、その新規塩形態およびその使用方法

Country Status (35)

Country Link
US (6) US7981906B2 (enExample)
EP (6) EP2465501B1 (enExample)
JP (4) JP2010535252A (enExample)
KR (2) KR20100063043A (enExample)
CN (4) CN101868237A (enExample)
AR (1) AR067775A1 (enExample)
AU (3) AU2008283813A1 (enExample)
BR (2) BRPI0815009A2 (enExample)
CA (2) CA2694510A1 (enExample)
CL (3) CL2008002271A1 (enExample)
CO (2) CO6260081A2 (enExample)
CY (1) CY1113561T1 (enExample)
DK (2) DK2182949T3 (enExample)
EC (2) ECSP10010007A (enExample)
ES (3) ES2606752T3 (enExample)
HR (1) HRP20130286T1 (enExample)
HU (1) HUE030387T2 (enExample)
IL (1) IL218976A0 (enExample)
ME (1) ME01508B (enExample)
MX (3) MX2010001293A (enExample)
MY (1) MY148002A (enExample)
NO (2) NO20100078L (enExample)
NZ (2) NZ582986A (enExample)
PE (3) PE20121821A1 (enExample)
PH (2) PH12012501513A1 (enExample)
PL (1) PL2182949T3 (enExample)
PT (1) PT2182949E (enExample)
RS (1) RS52743B (enExample)
RU (2) RU2012140182A (enExample)
SA (2) SA08290475B1 (enExample)
SI (1) SI2182949T1 (enExample)
TW (3) TW201402116A (enExample)
UY (1) UY31265A (enExample)
WO (2) WO2009018511A2 (enExample)
ZA (1) ZA201000719B (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6953855B2 (en) 1998-12-11 2005-10-11 Targacept, Inc. 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
US8314119B2 (en) * 2006-11-06 2012-11-20 Abbvie Inc. Azaadamantane derivatives and methods of use
SA08290475B1 (ar) * 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
EP2647373A1 (en) * 2008-05-12 2013-10-09 Targacept, Inc. Methods for preventing the development of retinopathy by the oral administration of exo-S-mecamylamine.
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
JO3250B1 (ar) 2009-09-22 2018-09-16 Novartis Ag إستعمال منشطات مستقبل نيكوتينيك أسيتيل كولين ألفا 7
JP5749797B2 (ja) 2010-05-17 2015-07-15 フォルム ファーマシューティカルズ、インコーポレイテッド (r)−7−クロロ−n−(キヌクリジン−3−イル)ベンゾ[b]チオフェン−2−カルボキサミド塩酸塩一水和物の結晶形
RU2013108223A (ru) * 2010-07-26 2014-09-10 Энвиво Фармасьютикалз, Инк. Лечение когнитивных нарушений определенными агонистами рецептора никотиновой кислоты альфа-7 в сочетании с ингибиторами ацетилхолинэстеразы
CA2809675A1 (en) 2010-09-23 2012-03-29 Shuang Chen Monohydrate of an azaadamantane derivative
TW201242600A (en) * 2011-01-18 2012-11-01 Targacept Inc Treatment of cognitive dysfunction in schizophrenia
US20140171448A1 (en) 2011-01-27 2014-06-19 Novartis Ag Use of nicotinic acetylcholine receptor alpha 7 activators
PL3156056T3 (pl) 2011-03-18 2024-04-29 Alkermes Pharma Ireland Limited Kompozycje farmaceutyczne zawierające estry sorbitanu
US20140228398A1 (en) 2011-03-18 2014-08-14 Novartis Ag COMBINATIONS OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATORS AND mGluR5 ANTAGONISTS FOR USE IN DOPAMINE INDUCED DYSKINESIA IN PARKINSON'S DISEASE
WO2012129262A1 (en) * 2011-03-23 2012-09-27 Targacept, Inc. Treatment of attention deficit/hyperactivity disease
JPWO2013002365A1 (ja) 2011-06-30 2015-02-23 東レ株式会社 止痒剤
TW201311698A (zh) * 2011-08-22 2013-03-16 Targacept Inc 作為神經元菸鹼乙醯膽鹼受體配位體之1,4-二氮雜雙環[3.2.2]壬烷
BR112014007485B1 (pt) 2011-10-20 2022-05-31 Novartis Ag Métodos para prever responsividade terapêutica de um indivíduo a tratamento com um ativador do receptor de acetilcolina nicotínico alfa 7, e usos do referido ativador
NZ630703A (en) * 2012-03-19 2017-02-24 Alkermes Pharma Ireland Ltd Pharmaceutical compositions comprising glycerol esters
JP6333802B2 (ja) 2012-03-19 2018-05-30 アルカームス ファーマ アイルランド リミテッド ベンジルアルコールを含む医薬組成物
JP6471089B2 (ja) 2012-03-19 2019-02-13 アルカームス ファーマ アイルランド リミテッド 脂肪酸エステルを含む医薬組成物
CA2872005A1 (en) 2012-05-08 2013-11-14 Forum Pharmaceuticals, Inc. Methods of maintaining, treating or improving cognitive function
AU2013349388B2 (en) 2012-09-19 2018-06-28 Alkermes Pharma Ireland Limited Pharmaceutical compositions having improved storage stability
CN104837499B (zh) 2012-12-11 2018-02-23 诺华有限公司 预测对α7烟碱型乙酰胆碱受体激活剂治疗响应性的生物标志物
JP6137336B2 (ja) 2013-01-15 2017-05-31 ノバルティス アーゲー ナルコレプシーの処置のためのアルファ7ニコチン性受容体アゴニストの使用
US20150313884A1 (en) 2013-01-15 2015-11-05 Novartis Ag Use of alpha 7 nicotinic acetylcholine receptor agonists
WO2014111837A1 (en) 2013-01-15 2014-07-24 Novartis Ag Use of alpha 7 nicotinic acetylcholine receptor agonists
CA2898080C (en) 2013-01-15 2018-01-09 Novartis Ag Use of alpha 7 nicotinic acetylcholine receptor agonists
WO2014153424A1 (en) * 2013-03-19 2014-09-25 La Jolla Institute For Allergy And Immunology Reducing diabetes in patients receiving hmg-coa reductase inhibitors (statins)
RU2688233C2 (ru) 2014-03-20 2019-05-21 Алкермес Фарма Айэленд Лимитед Препараты арипипразола, имеющие повышенные скорости впрыска
AU2015240465B2 (en) 2014-04-04 2020-02-27 Del Mar Pharmaceuticals Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
CN104288771B (zh) * 2014-09-30 2017-03-15 郑州大学第五附属医院 α7nAChR激动剂的新用途
US10857140B2 (en) 2015-05-06 2020-12-08 The Regents Of The University Of California K-Ras modulators
US9724340B2 (en) 2015-07-31 2017-08-08 Attenua, Inc. Antitussive compositions and methods
US10282666B1 (en) 2015-11-10 2019-05-07 Google Llc Coherency detection and information management system
RU2675111C2 (ru) * 2017-03-31 2018-12-17 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фундаментальной и клинической иммунологии" Способ стимуляции нейрогенеза в гиппокампе
AU2018255413A1 (en) 2017-04-20 2019-12-05 Leidos Biomedical Research, Inc. K-Ras modulators
AU2019230014B2 (en) 2018-03-05 2024-11-28 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy

Family Cites Families (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4203990A (en) 1979-04-30 1980-05-20 G. D. Searle & Co. Anti-diarrheal 2-substituted quinuclidines
EP0353189B1 (de) 1988-07-28 1994-01-12 Ciba-Geigy Ag Kupfer- und Nickeldihalogenidkomplexe, Verfahren zu deren Herstellung und deren Verwendung
US4922901A (en) 1988-09-08 1990-05-08 R. J. Reynolds Tobacco Company Drug delivery articles utilizing electrical energy
EP0402056A3 (en) 1989-06-06 1991-09-04 Beecham Group p.l.c. Azabicyclic compounds, process for their preparation and pharmaceutical compositions containing them
EP0412798A3 (en) 1989-08-08 1992-07-01 Merck Sharp & Dohme Ltd. Substituted pyridines, their preparation, formulations and use in dementia
IN173570B (enExample) 1989-11-23 1994-06-04 Pfizer
DK40890D0 (da) 1990-02-16 1990-02-16 Ferrosan As Substituerede urinstofforbindelser, deres fremstilling og anvendelse
EP0492903A1 (en) 1990-12-21 1992-07-01 MERCK SHARP & DOHME LTD. Substituted pyrazines, pyrimidines and pyridazines for use in the treatment of glaucoma
KR0175638B1 (ko) 1991-03-01 1999-02-18 카렌 에이.홀브루크 신경계 퇴행성 질환 치료용 니코틴 아날로그의 개량된 제조방법
US5212188A (en) 1992-03-02 1993-05-18 R. J. Reynolds Tabacco Company Method for treatment of neurodegenerative diseases
US5276043A (en) 1992-04-10 1994-01-04 R. J. Reynolds Tobacco Company Method for treatment of neurodegenerative diseases
KR100272614B1 (ko) 1992-08-31 2000-11-15 엠. 잭 오해니언 신경계의 퇴행성 질환의 치료에 유용한 아나바세인 유도체
US5977144A (en) 1992-08-31 1999-11-02 University Of Florida Methods of use and compositions for benzylidene- and cinnamylidene-anabaseines
IL107184A (en) 1992-10-09 1997-08-14 Abbott Lab Heterocyclic ether compounds that enhance cognitive function
US5852041A (en) 1993-04-07 1998-12-22 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acethylcholine receptors
IL109451A0 (en) * 1993-04-29 1994-07-31 Zeneca Ltd Heterocyclic derivatives
AU7474794A (en) 1993-07-22 1995-02-20 E.I. Du Pont De Nemours And Company Arthropodicidal azacyclic heterocycles
US5493026A (en) 1993-10-25 1996-02-20 Organix, Inc. Substituted 2-carboxyalkyl-3-(fluorophenyl)-8-(3-halopropen-2-yl) nortropanes and their use as imaging for agents for neurodegenerative disorders
US5510355A (en) 1994-09-06 1996-04-23 Bencherif; Merouane Depolarizing skeletal muscle relaxants
US5998404A (en) 1994-10-24 1999-12-07 Eli Lilly And Company Heterocyclic compounds and their use
US5604231A (en) 1995-01-06 1997-02-18 Smith; Carr J. Pharmaceutical compositions for prevention and treatment of ulcerative colitis
US5824692A (en) 1995-01-06 1998-10-20 Lippiello; Patrick Michael Pharmaceutical compositions for prevention and treatment of central nervous system disorders
US5597919A (en) 1995-01-06 1997-01-28 Dull; Gary M. Pyrimidinyl or Pyridinyl alkenyl amine compounds
US5616707A (en) 1995-01-06 1997-04-01 Crooks; Peter A. Compounds which are useful for prevention and treatment of central nervous system disorders
WO1996025160A1 (en) 1995-02-17 1996-08-22 Novo Nordisk A/S The use of heterocyclic compounds
US5585388A (en) 1995-04-07 1996-12-17 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acetylcholine receptors
US5583140A (en) 1995-05-17 1996-12-10 Bencherif; Merouane Pharmaceutical compositions for the treatment of central nervous system disorders
IL118279A (en) 1995-06-07 2006-10-05 Abbott Lab Compounds 3 - Pyridyloxy (or Thio) Alkyl Heterocyclic Pharmaceutical Compositions Containing Them and Their Uses for Preparing Drugs to Control Synaptic Chemical Transmission
JPH11508540A (ja) 1995-06-29 1999-07-27 ノボ ノルディスク アクティーゼルスカブ 新規の置換アザ環式またはアザ二環式化合物
JPH11512443A (ja) 1995-09-22 1999-10-26 ノボ ノルディスク アクティーゼルスカブ 新規な置換アザ環式またはアザ二環式化合物
US5712270A (en) 1995-11-06 1998-01-27 American Home Products Corporation 2-arylamidothiazole derivatives with CNS activity
US5616716A (en) 1996-01-06 1997-04-01 Dull; Gary M. (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds
SE9600683D0 (sv) * 1996-02-23 1996-02-23 Astra Ab Azabicyclic esters of carbamic acids useful in therapy
US5663356A (en) 1996-04-23 1997-09-02 Ruecroft; Graham Method for preparation of aryl substituted alefinic secondary amino compounds
US5726189A (en) 1996-05-03 1998-03-10 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Method for imaging nicotinic acetylcholinergic receptors in the brain using radiolabeled pyridyl-7-azabicyclo 2.2.1!heptanes
ZA9711092B (en) 1996-12-11 1999-07-22 Smithkline Beecham Corp Novel compounds.
US5861423A (en) 1997-02-21 1999-01-19 Caldwell; William Scott Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds
US5811442A (en) 1997-02-21 1998-09-22 Bencherif; Merouane Pharmaceutical compositions for the treatment of conditions associated with decreased blood flow
KR100589872B1 (ko) 1997-05-30 2006-06-15 뉴로서치 에이/에스 8-아자비사이클로(3,2,1)옥트-2-엔 유도체 및 이의 제조방법
AR013184A1 (es) * 1997-07-18 2000-12-13 Astrazeneca Ab Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis
US5952339A (en) 1998-04-02 1999-09-14 Bencherif; Merouane Pharmaceutical compositions and methods of using nicotinic antagonists for treating a condition or disorder characterized by alteration in normal neurotransmitter release
DK1068208T3 (da) 1998-04-02 2003-09-01 Targacept Inc Azatricyclo[3.3.1.1]dekanderivater og farmaceutiske sammensætninger, der indeholder dem
ATE255888T1 (de) 1998-06-01 2003-12-15 Ortho Mcneil Pharm Inc Tetrahydronaphtalene verbindungen und deren verwendung zur behandlung von neurodegenerativen krankheiten
US6310043B1 (en) 1998-08-07 2001-10-30 Governors Of The University Of Alberta Treatment of bacterial infections
GB9821503D0 (en) 1998-10-02 1998-11-25 Novartis Ag Organic compounds
US6432975B1 (en) 1998-12-11 2002-08-13 Targacept, Inc. Pharmaceutical compositions and methods for use
US6953855B2 (en) 1998-12-11 2005-10-11 Targacept, Inc. 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
US6734215B2 (en) 1998-12-16 2004-05-11 University Of South Florida Exo-S-mecamylamine formulation and use in treatment
SE9900100D0 (sv) 1999-01-15 1999-01-15 Astra Ab New compounds
FR2791678B1 (fr) 1999-03-30 2001-05-04 Synthelabo Derives de 1,4-diazabicyclo [3.2.2] nonane-4-carboxylates et -carboxamides, leur preparation et leur application en therapeutique
SE9904176D0 (sv) * 1999-11-18 1999-11-18 Astra Ab New use
SE0000540D0 (sv) 2000-02-18 2000-02-18 Astrazeneca Ab New compounds
GB0010955D0 (en) 2000-05-05 2000-06-28 Novartis Ag Organic compounds
BR0112297A (pt) 2000-06-27 2003-05-06 S A L V A T Lab Sa Compostos carbamatos derivados de arilalquilaminas
AU2001282873A1 (en) * 2000-08-18 2002-03-04 Pharmacia And Upjohn Company Quinuclidine-substituted aryl compounds for treatment of disease
WO2002016356A2 (en) 2000-08-18 2002-02-28 Pharmacia & Upjohn Company Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands)
WO2002016358A2 (en) 2000-08-18 2002-02-28 Pharmacia & Upjohn Company Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands)
WO2002017358A2 (en) 2000-08-21 2002-02-28 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists)
JP2004506734A (ja) 2000-08-21 2004-03-04 ファルマシア・アンド・アップジョン・カンパニー 疾患治療用のキヌクリド置換ヘテロアリール部分
US6599916B2 (en) 2000-08-21 2003-07-29 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease
EP1345937B1 (en) 2000-12-22 2005-09-28 Almirall Prodesfarma AG Quinuclidine carbamate derivatives and their use as m3 antagonists
US20020086871A1 (en) * 2000-12-29 2002-07-04 O'neill Brian Thomas Pharmaceutical composition for the treatment of CNS and other disorders
SI1397366T1 (sl) 2001-06-01 2007-06-30 Astrazeneca Ab Nov ligand za nikotinske acetilholinske receptorje, koristen v terapiji
US6569865B2 (en) * 2001-06-01 2003-05-27 Astrazeneca Ab Spiro 1-azabicyclo[2.2.2]octane-3,2′(3′h)-furo[2,3-b]pyridine
AR036040A1 (es) 2001-06-12 2004-08-04 Upjohn Co Compuestos de heteroarilo multiciclicos sustituidos con quinuclidinas y composiciones farmaceuticas que los contienen
WO2003011837A1 (en) 2001-08-01 2003-02-13 Merck & Co., Inc. Tyrosine kinase inhibitors
US6562816B2 (en) 2001-08-24 2003-05-13 Pharmacia & Upjohn Company Substituted-heteroaryl-7-aza[2.2.1]bicycloheptanes for the treatment of disease
BR0212123A (pt) 2001-08-24 2004-07-20 Upjohn Co 7-aza[2.2.1]biciclo-heptanos substituìdos com arila para o tratamento de doenças
EP1425286B1 (en) 2001-09-12 2007-02-28 Pharmacia & Upjohn Company LLC Substituted 7-aza-[2.2.1]bicycloheptanes for the treatment of diseases
CA2476681A1 (en) 2002-02-19 2003-08-28 Bruce N. Rogers Fused bicyclic-n-bridged-heteroaromatic carboxamides for the treatment of disease
MXPA04007083A (es) 2002-02-20 2004-10-29 Upjohn Co Compuestos azabiciclicos para el tratamiento de enfermedades.
DE60333746D1 (de) * 2002-04-18 2010-09-23 Astrazeneca Ab Thienylverbindungen
US7417049B2 (en) 2002-04-18 2008-08-26 Astrazeneca Ab Furyl compounds
EP1499616B1 (en) 2002-04-18 2009-06-17 AstraZeneca AB Heterocyclic compounds
US7176198B2 (en) * 2002-08-01 2007-02-13 Pfizer Inc. 1H-pyrazole and 1H-pyrrole-azabicyclic compounds for the treatment of disease
SE0202465D0 (sv) 2002-08-14 2002-08-14 Astrazeneca Ab New compounds
ATE384720T1 (de) 2002-08-14 2008-02-15 Neurosearch As Chinucledin - derivate und deren verwendung
SE0202430D0 (sv) 2002-08-14 2002-08-14 Astrazeneca Ab New Compounds
JP2006501246A (ja) 2002-08-30 2006-01-12 メモリー・ファーマシューティカルズ・コーポレイション 神経変性疾患の治療において有用なアナバセイン誘導体
AU2003276919B2 (en) 2002-09-25 2013-05-16 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof
BR0315056A (pt) 2002-11-01 2005-08-16 Pharmacia & Upjohn Co Llc Compostos tendo tanto atividade agonista nicotìnica de alfa7 quanto atividade antagonista de 5ht3 para o tratamento de doenças do sistema nervoso central
WO2004039366A1 (en) 2002-11-01 2004-05-13 Pharmacia & Upjohn Company Llc Nicotinic acetylcholine agonists in the treatment of glaucoma and retinal neuropathy
CN1735414A (zh) 2002-12-06 2006-02-15 北岸长岛犹太人研究学院 用α7受体结合类胆碱激动剂抑制炎症
HRP20050522A2 (en) 2002-12-11 2005-12-31 Pharmacia & Upjohn Company Llc Combination for the treatment of adhd
MXPA05005666A (es) 2002-12-11 2005-07-26 Pharmacia & Upjohn Co Llc Tratamiento de enfermedades con combinaciones de agonistas del receptor nicotinico de acetilcolina alfa-7 y otros compuestos.
US6917746B2 (en) 2002-12-17 2005-07-12 3M Innovative Properties Company Apparatus and method for creating a fiber optic circuit
US6777617B2 (en) 2002-12-30 2004-08-17 3M Innovative Properties Company Telecommunications terminal
MXPA05006861A (es) 2003-02-27 2005-12-12 Neurosearch As Derivados arildiazabiciclicos novedosos.
CN1829721A (zh) 2003-07-08 2006-09-06 阿斯利康(瑞典)有限公司 对α7烟碱乙酰胆碱受体具有亲和力的螺[1-氮杂二环[2.2.2]辛烷-3,5’-噁唑烷]-2’-酮衍生物
MXPA06003196A (es) 2003-09-25 2006-06-23 Astrazeneca Ab Ligandos.
CN100494202C (zh) 2003-10-21 2009-06-03 阿斯利康(瑞典)有限公司 螺呋喃并吡啶芳基衍生物
US7160876B2 (en) 2003-12-22 2007-01-09 Abbott Laboratories Fused bicycloheterocycle substituted quinuclidine derivatives
US20050137217A1 (en) 2003-12-22 2005-06-23 Jianguo Ji Spirocyclic quinuclidinic ether derivatives
US20050137203A1 (en) 2003-12-22 2005-06-23 Jianguo Ji 3-quinuclidinyl amino-substituted biaryl derivatives
US20050245531A1 (en) 2003-12-22 2005-11-03 Abbott Laboratories Fused bicycloheterocycle substituted quinuclidine derivatives
US20050137398A1 (en) 2003-12-22 2005-06-23 Jianguo Ji 3-Quinuclidinyl heteroatom bridged biaryl derivatives
JP2007520527A (ja) * 2004-02-04 2007-07-26 ノイロサーチ アクティーゼルスカブ ニコチン性アセチルコリン受容体リガンドとしてのジアザ2環式アリール誘導体
JP2007534692A (ja) 2004-04-22 2007-11-29 メモリー・ファーマシューティカルズ・コーポレイション インドール、1h−インダゾール、1,2−ベンズイソキサゾール、1,2−ベンゾイソチアゾール、ならびにその調製および使用
US7632831B2 (en) 2004-05-07 2009-12-15 Memory Pharmaceuticals Corporation 1H-indazoles, benzothiazoles, 1,2-benzoisoxazoles, 1,2-benzoisothiazoles, and chromones and preparation and uses thereof
CN101035792B (zh) * 2004-10-20 2010-09-15 神经研究公司 新颖的二氮杂双环芳基衍生物和它们的医药用途
WO2006065209A1 (en) 2004-12-15 2006-06-22 Astrazeneca Ab Nicotinic acetylcholine receptor ligands
RU2418797C2 (ru) * 2004-12-22 2011-05-20 Мемори Фармасьютиклз Корпорейшн Лиганды никотинового рецептора альфа-7, их получение и применение
EP1891036A4 (en) 2005-06-07 2010-08-04 Univ Florida SELECTIVE LIGANDS FOR ALPHA-7 NICOTINE RECEPTORS
DE602006017235D1 (de) * 2005-08-22 2010-11-11 Targacept Inc Heteroarylsubstituierte diazatricycloalkane, verfahren zu deren herstellung und deren anwendung
CA2622677A1 (en) 2005-09-23 2007-04-05 Richard Schumacher Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof
US8316104B2 (en) * 2005-11-15 2012-11-20 California Institute Of Technology Method and apparatus for collaborative system
SA08290475B1 (ar) * 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
RU2481123C2 (ru) * 2008-02-13 2013-05-10 Таргасепт, Инк. Комбинация агонистов альфа 7 никотиновых рецепторов и антипсихотических средств

Similar Documents

Publication Publication Date Title
JP2010535252A5 (enExample)
CN101534809B (zh) 取代的2-氨基1,2,3,4-四氢化萘在制备预防、减轻和/或治疗各类疼痛的药物中的用途
JP2008007519A5 (enExample)
FI3287124T3 (fi) Ketamiinin oraalinen annosmuoto
JP2007504174A5 (enExample)
JP2009542702A5 (enExample)
MX2010005342A (es) Compuestos indola y metodos para tratar el dolor visceral.
JP2009542699A5 (enExample)
JP2013525444A5 (enExample)
NZ593754A (en) Dpp-iv inhibitors for treatment of diabetes in paediatric patients
JP2011516417A5 (enExample)
WO2011014255A8 (en) Treatment of crohn's disease with laquinimod
JP2016185995A5 (enExample)
CN1440283A (zh) 有机化合物的联合形式
RU2010143864A (ru) Способы лечения нарушений с применением селективного антагониста nr2b-подтипа nmda рецепторов
EP2283843A3 (en) Opioids for the treatment of the chronic obstructive pulmonary disease (COPD)
NZ613291A (en) Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
JP2008535785A5 (enExample)
WO2007105113A3 (en) Use of crf1 receptor antagonists for preparing a drug for treating metabolic syndrome and/or obesity and/or dyslipoproteinemia
PH12014502448A1 (en) Pharmaceutical combinations for the treatment of metabolic disorders
US20140045801A1 (en) Pramipexole transdermal delivery for severe headaches
JP2012531402A5 (enExample)
WO2007145863A3 (en) Sustained release formulation of naltrexone
RS51388B2 (sr) Primena jedne kombinacije morfina i najmanje jednog opijat antagonista za tretman zavisnosti od opijata i za smanjenje neoralne zloupotrebe kod zavisnika od opijata
JP2008538582A (ja) 精神病性障害の治療または予防のための新規の治療的組み合わせ